Author

Ashley P. Ghiaseddin

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

18 TTFields with maintenance temozolomide/pembrolizumab versus TTFields with maintenance temozolomide/placebo for newly diagnosed glioblastoma: the phase 3 EF-41/KEYNOTE D58 trial

With the current standard-of-care for glioblastoma (maximal safe resection followed by radiotherapy with concurrent TMZ, then maintenance temozolomide/TTFields), median overall survival (OS) is approximately 21 months. Immune checkpoint inhibitors have not demonstrated meaningful clinical benefit in glioblastoma,...

G. Borst, David D. Tran, Ashley P. Ghiaseddin et al. · Neuro-Oncology · 0 citations

Open access Aug 2026

CLTR-03 IMPACT-MET: A PHASE I STUDY TO ASSESS SAFETY AND FEASIBILITY OF IL-8 RECEPTOR MODIFIED, PATIENT-DERIVED, ACTIVATED CD70 CAR T CELL THERAPY IN ADULTS WITH BRAIN METASTASES FROM PRIMARY CANCERS

This study will evaluate the safety and feasibility of 8R-70CAR T cells in BM patients and may inform on the future development of 8R-70CAR T cell therapy in this population.

Taryn King, A. Fares, P. Deleyrolle et al. · Neuro-Oncology Advances · 1 citation